EX-99.2 3 a2024q4exhibit992.htm EX-99.2

Exhibit 99.2

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			FOURTH QUARTER
									Percent Change
Sales to customers by geographic area			2024			2023			Total			Operations			Currency
U.S.			$13,204			12,009			10.0		%	10.0			—
Europe			4,921			4,962			(0.8)			(0.2)			(0.6)
Western Hemisphere excluding U.S.			1,135			1,166			(2.7)			17.6			(20.3)
Asia-Pacific, Africa			3,260			3,258			0.1			0.9			(0.8)
International			9,316			9,386			(0.7)			2.5			(3.2)
Worldwide			$22,520			21,395			5.3		%	6.7			(1.4)

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			FOURTH QUARTER
									Percent Change
Sales to customers by geographic area (ex. COVID-19 Vaccine)			2024			2023			Total			Operations			Currency
U.S.*			$13,204			12,009			10.0		%	10.0			—
Europe(1)			4,921			4,918			0.1			0.7			(0.6)
Western Hemisphere excluding U.S.*			1,135			1,166			(2.7)			17.6			(20.3)
Asia-Pacific, Africa*			3,260			3,258			0.1			0.9			(0.8)
International			9,316			9,342			(0.3)			2.9			(3.2)
Worldwide			$22,520			21,351			5.5		%	6.9			(1.4)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(1) Refer to supplemental sales information schedules

*No COVID-19 Vaccine Sales

---

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			TWELVE MONTHS
									Percent Change
Sales to customers by geographic area			2024			2023			Total			Operations			Currency
U.S.			$50,302			46,444			8.3		%	8.3			—
Europe			20,212			20,410			(1.0)			(0.6)			(0.4)
Western Hemisphere excluding U.S.			4,714			4,549			3.6			20.4			(16.8)
Asia-Pacific, Africa			13,593			13,756			(1.2)			2.3			(3.5)
International			38,519			38,715			(0.5)			2.9			(3.4)
Worldwide			$88,821			85,159			4.3		%	5.9			(1.6)

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			TWELVE MONTHS
									Percent Change
Sales to customers by geographic area (ex. COVID-19 Vaccine)			2024			2023			Total			Operations			Currency
U.S.*			$50,302			46,444			8.3		%	8.3			—
Europe(1)			20,014			19,293			3.7			4.1			(0.4)
Western Hemisphere excluding U.S.*			4,714			4,549			3.6			20.4			(16.8)
Asia-Pacific, Africa*			13,593			13,756			(1.2)			2.3			(3.5)
International			38,321			37,598			1.9			5.5			(3.6)
Worldwide			$88,623			84,042			5.5		%	7.0			(1.5)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(1) Refer to supplemental sales information schedules

*No COVID-19 Vaccine Sales

---

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			FOURTH QUARTER
												Percent Change
Sales to customers by segment of business						2024			2023			Total			Operations			Currency
Innovative Medicine (1)
U.S.						$	8,977		8,079			11.1		%	11.1			—
International						5,355			5,643			(5.1)			(1.0)			(4.1)
						14,332			13,722			4.4			6.1			(1.7)
Innovative Medicine excluding COVID-19 Vaccine (1)
U.S.						8,977			8,079			11.1			11.1			—
International						5,355			5,599			(4.4)			(0.3)			(4.1)
						14,332			13,678			4.8			6.5			(1.7)
MedTech
U.S.						4,227			3,930			7.6			7.6			—
International						3,961			3,743			5.8			7.6			(1.8)
						8,188			7,673			6.7			7.6			(0.9)
U.S.						13,204			12,009			10.0			10.0			—
International						9,316			9,386			(0.7)			2.5			(3.2)
Worldwide						22,520			21,395			5.3			6.7			(1.4)
U.S.						13,204			12,009			10.0			10.0			—
International						9,316			9,342			(0.3)			2.9			(3.2)
Worldwide excluding COVID-19 Vaccine (1)						$	22,520		21,351			5.5		%	6.9			(1.4)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(1)Refer to supplemental sales information schedules.

---

Johnson & Johnson and subsidiaries

Supplementary sales data

(Unaudited; Dollars in Millions)			TWELVE MONTHS
									Percent Change
Sales to customers by segment of business			2024			2023			Total			Operations			Currency
Innovative Medicine (1)
U.S.			$33,970			31,169			9.0		%	9.0			—
International			22,994			23,590			(2.5)			1.3			(3.8)
			56,964			54,759			4.0			5.7			(1.7)
Innovative Medicine excluding COVID-19 Vaccine (1)
U.S.			33,970			31,169			9.0			9.0			—
International			22,796			22,473			1.4			5.5			(4.1)
			56,766			53,642			5.8			7.5			(1.7)
MedTech
U.S.			16,332			15,275			6.9			6.9			—
International			15,525			15,125			2.6			5.4			(2.8)
			31,857			30,400			4.8			6.2			(1.4)
U.S.			50,302			46,444			8.3			8.3			—
International			38,519			38,715			(0.5)			2.9			(3.4)
Worldwide			88,821			85,159			4.3			5.9			(1.6)
U.S.			50,302			46,444			8.3			8.3			—
International			38,321			37,598			1.9			5.5			(3.6)
Worldwide excluding COVID-19 Vaccine (1)			$88,623			84,042			5.5		%	7.0			(1.5)

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

(1)Refer to supplemental sales information schedules.

---

Johnson & Johnson and subsidiaries

Condensed consolidated statement of earnings

(Unaudited; in Millions Except Per Share Figures)			FOURTH QUARTER
			2024						2023						Percent Increase (Decrease)
			Amount			Percent to Sales			Amount			Percent to Sales
Sales to customers			$	22,520		100.0			$21,395			100.0			5.3
Cost of products sold			7,128			31.6			6,798			31.8			4.9
Gross Profit			15,392			68.4			14,597			68.2			5.4
Selling, marketing and administrative expenses			6,453			28.6			5,810			27.1			11.1
Research and development expense			5,298			23.5			4,480			20.9			18.3
In-process research and development impairments			17			0.1			58			0.3
Interest (income) expense, net			(144)			(0.6)			(212)			(1.0)
Other (income) expense, net			(161)			(0.7)			(421)			(2.0)
Restructuring			42			0.2			56			0.3
Earnings before provision for taxes on income			3,887			17.3			4,826			22.6			(19.5)
Provision for taxes on income			456			2.1			694			3.3			(34.3)
Net earnings from Continuing Operations			$3,431			15.2			$4,132			19.3			(17.0)
Net earnings/(loss) from Discontinued Operations, net of tax			—						(83)
Net earnings			$3,431						$4,049
Net earnings per share (Diluted) from Continuing Operations			$	1.41					$	1.70					(17.1)
Net earnings/(loss) per share (Basic) from Discontinued Operations*			$	—					$	(0.03)
Average shares outstanding (Diluted)			2,427.1						2,430.7
Effective tax rate from Continuing Operations			11.7		%				14.4		%
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income from Continuing Operations			$	5,421		24.1			$	6,237		29.2			(13.1)
Net earnings from Continuing Operations			$	4,946		22.0			$	5,562		26.0			(11.1)
Net earnings per share (Diluted) from Continuing Operations			$	2.04					$	2.29					(10.9)
Effective tax rate from Continuing Operations			8.8		%				10.8		%

* Basic shares of 2,407.2 are used to calculate loss per share in the fourth quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive.

(1) See Reconciliation of Non-GAAP Financial Measures.

(A)    NON-GAAP FINANCIAL MEASURES "Adjusted earnings from continuing operations before provision for taxes on income," "adjusted net earnings from continuing operations," "adjusted net earnings per share (diluted) from continuing operations," and "adjusted effective tax rate from continuing operations" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations prepared in accordance with GAAP, adjusted earnings from continuing operations before provision for taxes on income, adjusted net earnings from continuing operations, adjusted net earnings per share (diluted) from continuing operations, and adjusted effective tax rate from continuing operations may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

---

Johnson & Johnson and subsidiaries

Condensed consolidated statement of earnings

(Unaudited; in Millions Except Per Share Figures)			TWELVE MONTHS
			2024						2023						Percent Increase (Decrease)
			Amount			Percent to Sales			Amount			Percent to Sales
Sales to customers			$	88,821		100.0			$	85,159		100.0			4.3
Cost of products sold			27,471			30.9			26,553			31.2			3.5
Gross Profit			61,350			69.1			58,606			68.8			4.7
Selling, marketing and administrative expenses			22,869			25.7			21,512			25.2			6.3
Research and development expense			17,232			19.4			15,085			17.7			14.2
In-process research and development impairments			211			0.2			313			0.4
Interest (income) expense, net			(577)			(0.6)			(489)			(0.6)
Other (income) expense, net			4,694			5.3			6,634			7.8
Restructuring			234			0.3			489			0.6
Earnings before provision for taxes on income			16,687			18.8			15,062			17.7			10.8
Provision for taxes on income			2,621			3.0			1,736			2.1			51.0
Net earnings from Continuing Operations			$14,066			15.8			$	13,326		15.6			5.6
Net earnings from Discontinued Operations, net of tax			—						21,827
Net earnings			$14,066						$	35,153
Net earnings per share (Diluted) from Continuing Operations			$	5.79					$	5.20					11.3
Net earnings per share (Diluted) from Discontinued Operations			$	—					$	8.52
Average shares outstanding (Diluted)			2,429.4						2,560.4
Effective tax rate from Continuing Operations			15.7		%				11.5		%
Adjusted earnings from Continuing Operations before provision for taxes and net earnings (1) (A)
Earnings before provision for taxes on income from Continuing Operations			$	28,979		32.6			$	29,811		35.0			(2.8)
Net earnings from Continuing Operations			$	24,242		27.3			$	25,409		29.8			(4.6)
Net earnings per share (Diluted) from Continuing Operations			$	9.98					$	9.92					0.6
Effective tax rate from Continuing Operations			16.3		%				14.8		%

(1)See Reconciliation of Non-GAAP Financial Measures.

(A)NON-GAAP FINANCIAL MEASURES "Adjusted earnings from continuing operations before provision for taxes on income," "adjusted net earnings from continuing operations," "adjusted net earnings per share (diluted) from continuing operations," and "adjusted effective tax rate from continuing operations" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant gains from divestitures, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings from continuing operations before provision for taxes on income, net earnings from continuing operations, net earnings per share (diluted) from continuing operations, and effective tax rate from continuing operations prepared in accordance with GAAP, adjusted earnings from continuing operations before provision for taxes on income, adjusted net earnings from continuing operations, adjusted net earnings per share (diluted) from continuing operations, and adjusted effective tax rate from continuing operations may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, significant gains from divestitures, the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

---

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

			Fourth Quarter
(Dollars in Millions Except Per Share Data)			2024									2023
Net Earnings from Continuing Operations, after tax- as reported						$3,431						$4,132
Pre-tax Adjustments
Litigation related						(16)						166
Intangible Asset Amortization expense						1,171						1,148
COVID-19 Vaccine related costs 1						23						10
Restructuring related 2						62						139
Medical Device Regulation 3						47						88
Acquisition, integration and divestiture related						298						237
(Gains)/losses on securities						(68)						(435)
IPR&D impairments						17						58
Tax Adjustments
Tax impact on special item adjustments 4						(80)						75
Tax legislation and other tax related						61						(56)
Adjusted Net Earnings from Continuing Operations, after tax						$4,946						$5,562
Average shares outstanding (Diluted)						2,427.1						2,430.7
Adjusted net earnings per share from Continuing Operations (Diluted)						$2.04						$2.29
Operational adjusted net earnings per share from Continuing Operations (Diluted)						$2.05

Notes:

1COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments which was completed in Q4 2024.

2In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million Q4 2024 YTD and $55 million in the fiscal fourth quarter of 2023 ($479 million Q4 2023 YTD) includes the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.

In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) and $84 million in the fiscal fourth quarter of 2023 ($319 million Q4 2023 YTD) primarily includes costs related to market and product exits.

3European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance. The implementation was substantially completed as of Q4 2024, and ongoing costs will be reflected in MedTech's operating results beginning in 2025.

4The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

---

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

			Twelve Months Ended
(Dollars in Millions Except Per Share Data)			2024						2023
Net Earnings from Continuing Operations, after tax- as reported						$14,066						$13,326
Pre-tax Adjustments
Litigation related						5,450						7,152
Intangible Asset Amortization expense						4,526						4,532
COVID-19 Vaccine related costs 1						100						663
Restructuring related 2						269						798
Medical Device Regulation 3						204						311
Acquisition, integration and divestiture related						1,226						339
(Gains)/losses on securities						306						641
IPR&D impairments						211						313
Tax Adjustments
Tax impact on special item adjustments 4						(2,135)						(2,694)
Tax legislation and other tax related						19						28
Adjusted Net Earnings from Continuing Operations, after tax						$24,242						$25,409
Average shares outstanding (Diluted)						2,429.4						2,560.4
Adjusted net earnings per share from Continuing Operations (Diluted)						$9.98						$9.92
Operational adjusted net earnings per share from Continuing Operations (Diluted)						$9.99

Notes:

1COVID-19 Vaccine related costs include remaining commitments and obligations, including external manufacturing network exit costs and required clinical trial expenses, associated with the Company's completion of its COVID-19 vaccine contractual commitments which was completed in Q4 2024.

2In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million Q4 2024 YTD and $55 million in the fiscal fourth quarter of 2023 ($479 million Q4 2023 YTD) includes the termination of partnered and non-partnered program costs, asset impairments and asset divestments. This program was completed in Q4 2024.

In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expense of $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) and $84 million in the fiscal fourth quarter of 2023 ($319 million Q4 2023 YTD) primarily includes costs related to market and product exits.

3European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company’s previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices were required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its MedTech operating segments' measures of profit and loss used for making operating decisions and assessing performance. The implementation was substantially completed as of Q4 2024, and ongoing costs will be reflected in MedTech's operating results beginning in 2025.

4The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

---

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

Adjusted operational sales growth(A)

Fourth quarter 2024 actual vs. 2023 actual

Segments
						Innovative Medicine						MedTech						Total
WW As Reported						4.4		%				6.7		%				5.3		%
U.S.						11.1		%				7.6		%				10.0		%
International						(5.1		%)				5.8		%				(0.7		%)
WW Currency						(1.7)						(0.9)						(1.4)
U.S.						—						—						—
International						(4.1)						(1.8)						(3.2)
WW Operational						6.1		%				7.6		%				6.7		%
U.S.						11.1		%				7.6		%				10.0		%
International						(1.0		%)				7.6		%				2.5		%
Shockwave												(3.4)						(1.2)
U.S.												(5.1)						(1.7)
International												(1.5)						(0.6)
All Other Acquisitions and Divestitures (A&D)						0.2						0.4						0.2
U.S.						0.1						0.8						0.3
International						0.3						0.0						0.1
WW Adjusted Operational Ex A&D						6.3		%				4.6		%				5.7		%
U.S.						11.2		%				3.3		%				8.6		%
International						(0.7		%)				6.1		%				2.0		%
COVID-19 Vaccine						0.4												0.2
U.S.						0.0												0.0
International						0.7												0.4
WW Adjusted Operational Ex A&D & COVID-19 Vaccine						6.7		%				4.6		%				5.9		%
U.S.						11.2		%				3.3		%				8.6		%
International						0.0		%				6.1		%				2.4		%

Note: Percentages are based on actual, non-rounded figures and may not sum

(A)    NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

---

Johnson & Johnson and subsidiaries

Reconciliation of non-GAAP financial measures

Adjusted operational sales growth(A)

Twelve months 2024 actual vs. 2023 actual

Segments
						Innovative Medicine						MedTech						Total
WW As Reported						4.0		%				4.8		%				4.3		%
U.S.						9.0		%				6.9		%				8.3		%
International						(2.5)		%				2.6		%				(0.5)		%
WW Currency						(1.7)						(1.4)						(1.6)
U.S.						—						—						—
International						(3.8)						(2.8)						(3.4)
WW Operational						5.7		%				6.2		%				5.9		%
U.S.						9.0		%				6.9		%				8.3		%
International						1.3		%				5.4		%				2.9		%
Shockwave												(1.9)						(0.7)
U.S.												(2.9)						(1.0)
International												(0.8)						(0.3)
All Other Acquisitions and Divestitures (A&D)						0.1						0.4						0.2
U.S.						0.1						0.8						0.3
International						0.2						0.1						0.1
WW Adjusted Operational Ex A&D						5.8		%				4.7		%				5.4		%
U.S.						9.1		%				4.8		%				7.6		%
International						1.5		%				4.7		%				2.7		%
COVID-19 Vaccine						1.8												1.1
U.S.						0.0												0.0
International						4.2												2.6
WW Adjusted Operational Ex A&D & COVID-19 Vaccine						7.6		%				4.7		%				6.5		%
U.S.						9.1		%				4.8		%				7.6		%
International						5.7		%				4.7		%				5.3		%

Note: Percentages are based on actual, non-rounded figures and may not sum

(A)    NON-GAAP FINANCIAL MEASURE “Adjusted operational sales growth" excludes acquisitions, divestitures and translational currency and is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures, and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			FOURTH QUARTER
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)
IMMUNOLOGY
US			$2,856						3,033						(5.9)		%	(5.9)		%	—		%
Intl			1,383						1,562						(11.5)			(6.5)			(5.0)
WW			4,238						4,595						(7.8)			(6.1)			(1.7)
REMICADE
US			231						294						(21.4)			(21.4)			—
US Exports(3)			9						35						(73.3)			(73.3)			—
Intl			117						100						16.5			22.9			(6.4)
WW			359						429						(16.5)			(15.0)			(1.5)
SIMPONI / SIMPONI ARIA
US			262						258						1.3			1.3			—
Intl			321						244						32.1			44.2			(12.1)
WW			583						502						16.2			22.1			(5.9)
STELARA
US			1,699						1,786						(4.9)			(4.9)			—
Intl			650						967						(32.7)			(29.6)			(3.1)
WW			2,349						2,753						(14.7)			(13.6)			(1.1)
TREMFYA
US			654						657						(0.6)			(0.6)			—
Intl			295						252						16.9			21.7			(4.8)
WW			949						910						4.2			5.6			(1.4)
OTHER IMMUNOLOGY
US			0						2						*			*			—
Intl			0						0						—			—			—
WW			0						2						*			*			*
INFECTIOUS DISEASES
US			331						353						(6.4)			(6.4)			—
Intl			443						498						(11.2)			(9.8)			(1.4)
WW			774						852						(9.2)			(8.4)			(0.8)
COVID-19 VACCINE
US			0						0						—			—			—
Intl			0						44						*			*			*
WW			0						44						*			*			*
EDURANT / rilpivirine
US			7						9						(10.1)			(10.1)			—
Intl			315						299						5.0			5.6			(0.6)
WW			322						307						4.6			5.1			(0.5)
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US			321						341						(5.8)			(5.8)			—
Intl			86						98						(12.9)			(8.9)			(4.0)
WW			407						439						(7.4)			(6.5)			(0.9)
OTHER INFECTIOUS DISEASES
US			1						4						(53.1)			(53.1)			—
Intl			43						58						(24.2)			(22.4)			(1.8)
WW			45						62						(26.1)			(24.4)			(1.7)

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			FOURTH QUARTER
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
NEUROSCIENCE
US			$1,148						1,022						12.3		%	12.3		%	—		%
Intl			628						780						(19.6)			(16.8)			(2.8)
WW			1,775						1,801						(1.5)			(0.3)			(1.2)
CONCERTA / methylphenidate
US			33						39						(12.8)			(12.8)			—
Intl			125						142						(11.5)			(7.7)			(3.8)
WW			159						180						(11.7)			(8.8)			(2.9)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
US			796						733						8.6			8.6			—
Intl			267						278						(4.0)			(1.8)			(2.2)
WW			1,063						1,011						5.1			5.7			(0.6)
SPRAVATO
US			269						180						50.1			50.1			—
Intl			28						26						7.1			12.5			(5.4)
WW			297						206						44.6			45.3			(0.7)
OTHER NEUROSCIENCE
US			49						71						(31.0)			(31.0)			—
Intl			206						334						(38.1)			(35.4)			(2.7)
WW			255						404						(36.9)			(34.6)			(2.3)
ONCOLOGY
US			3,019						2,285						32.2			32.2			—
Intl			2,476						2,334						6.1			10.6			(4.5)
WW			5,497						4,618						19.0			21.3			(2.3)
CARVYKTI
US			304						145						*			*			—
Intl			31						13						*			*			*
WW			334						159						*			*			*
DARZALEX
US			1,799						1,395						28.9			28.9			—
Intl			1,285						1,155						11.3			17.0			(5.7)
WW			3,084						2,550						20.9			23.5			(2.6)
ERLEADA
US			342						287						19.0			19.0			—
Intl			442						361						22.4			25.7			(3.3)
WW			784						647						20.9			22.7			(1.8)
IMBRUVICA
US			250						255						(2.0)			(2.0)			—
Intl			481						533						(9.6)			(6.8)			(2.8)
WW			731						788						(7.2)			(5.2)			(2.0)
TECVAYLI
US			108						102						5.6			5.6			—
Intl			38						24						59.9			71.6			(11.7)
WW			146						126						15.8			18.0			(2.2)
ZYTIGA / abiraterone acetate
US			9						9						(7.3)			(7.3)			—
Intl			127						191						(33.6)			(30.7)			(2.9)
WW			135						201						(32.4)			(29.6)			(2.8)
OTHER ONCOLOGY
US			208						90						*			*			—
Intl			74						58						25.5			30.6			(5.1)
WW			282						148						90.4			92.4			(2.0)

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			FOURTH QUARTER
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
PULMONARY HYPERTENSION
US			$	819					733						11.6		%	11.6		%	—		%
Intl			274						282						(3.2)			1.2			(4.4)
WW			1,092						1,017						7.4			8.7			(1.3)
OPSUMIT
US			385						368						4.8			4.8			—
Intl			160						169						(5.2)			(2.5)			(2.7)
WW			545						536						1.7			2.5			(0.8)
UPTRAVI
US			391						348						12.3			12.3			—
Intl			75						70						5.7			11.2			(5.5)
WW			465						419						11.2			12.1			(0.9)
OTHER PULMONARY HYPERTENSION
US			42						18						*			*			—
Intl			40						45						(10.0)			(0.4)			(9.6)
WW			82						61						32.3			39.3			(7.0)
CARDIOVASCULAR / METABOLISM / OTHER
US			805						652						23.3			23.3			—
Intl			153						185						(17.6)			(15.1)			(2.5)
WW			957						837						14.3			14.8			(0.5)
XARELTO
US			676						525						28.5			28.5			—
Intl			—						—						—			—			—
WW			676						525						28.5			28.5			—
OTHER
US			130						127						1.5			1.5			—
Intl			153						185						(17.6)			(15.1)			(2.5)
WW			281						312						(9.8)			(8.3)			(1.5)
TOTAL INNOVATIVE MEDICINE
US			8,977						8,079						11.1			11.1			—
Intl			5,355						5,643						(5.1)			(1.0)			(4.1)
WW			$	14,332					13,722						4.4		%	6.1		%	(1.7)		%

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			FOURTH QUARTER
															% Change
			2024						2023						Reported			Operational(1)			Currency
MEDTECH SEGMENT(2)
CARDIOVASCULAR(4)
US			$	1,221					971						25.8		%	25.8		%	—		%
Intl			841						698						20.6			22.0			(1.4)
WW			2,062						1,669						23.6			24.2			(0.6)
ELECTROPHYSIOLOGY
US			681						667						2.1			2.1			—
Intl			640						572						11.7			13.3			(1.6)
WW			1,321						1,239						6.6			7.3			(0.7)
ABIOMED
US			308						276						11.3			11.3			—
Intl			77						64						19.8			21.1			(1.3)
WW			384						340						12.9			13.2			(0.3)
SHOCKWAVE(5)
US			202						—						*			*			—
Intl			56						—						*			*			—
WW			258						—						*			*			—
OTHER CARDIOVASCULAR(4)
US			31						28						11.1			11.1			—
Intl			68						61						12.1			12.3			(0.2)
WW			99						89						11.8			12.0			(0.2)
ORTHOPAEDICS
US			1,460						1,425						2.4			2.4			—
Intl			856						843						1.6			2.5			(0.9)
WW			2,315						2,268						2.1			2.5			(0.4)
HIPS
US			272						266						2.5			2.5			—
Intl			146						132						10.6			11.7			(1.1)
WW			418						398						5.2			5.6			(0.4)
KNEES
US			238						242						(1.5)			(1.5)			—
Intl			160						144						10.7			11.3			(0.6)
WW			398						387						3.1			3.3			(0.2)
TRAUMA
US			514						487						5.5			5.5			—
Intl			250						255						(1.9)			(0.5)			(1.4)
WW			764						741						3.0			3.5			(0.5)
SPINE, SPORTS & OTHER
US			434						430						1.1			1.1			—
Intl			300						311						(3.6)			(2.9)			(0.7)
WW			735						742						(0.9)			(0.6)			(0.3)

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			FOURTH QUARTER
															% Change
			2024						2023						Reported			Operational(1)			Currency
MEDTECH SEGMENT(2)(Continued)
SURGERY
US			$1,038						1,047						(0.9)		%	(0.9)		%	—		%
Intl			1,469						1,484						(1.0)			1.4			(2.4)
WW			2,507						2,530						(0.9)			0.4			(1.3)
ADVANCED
US			478						468						2.0			2.0			—
Intl			673						698						(3.6)			(1.6)			(2.0)
WW			1,151						1,167						(1.4)			(0.1)			(1.3)
GENERAL
US			560						579						(3.1)			(3.1)			—
Intl			795						785						1.4			4.0			(2.6)
WW			1,357						1,364						(0.5)			1.0			(1.5)
VISION
US			509						487						4.5			4.5			—
Intl			794						721						10.2			12.2			(2.0)
WW			1,303						1,208						7.9			9.1			(1.2)
CONTACT LENSES / OTHER
US			396						374						6.0			6.0			—
Intl			541						508						6.4			8.5			(2.1)
WW			937						882						6.3			7.4			(1.1)
SURGICAL
US			113						114						(0.4)			(0.4)			—
Intl			252						212						19.3			21.1			(1.8)
WW			365						326						12.4			13.6			(1.2)
TOTAL MEDTECH
US			4,227						3,930						7.6			7.6			—
Intl			3,961						3,743						5.8			7.6			(1.8)
WW			$8,188						7,673						6.7		%	7.6		%	(0.9)		%

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			TWELVE MONTHS
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)
IMMUNOLOGY
US			$11,355						11,539						(1.6)		%	(1.6)		%	—		%
Intl			6,473						6,513						(0.6)			4.0			(4.6)
WW			17,828						18,052						(1.2)			0.4			(1.6)
REMICADE
US			1,009						1,143						(11.7)			(11.7)			—
US Exports(3)			98						147						(33.0)			(33.0)			—
Intl			497						549						(9.5)			(5.0)			(4.5)
WW			1,605						1,839						(12.8)			(11.4)			(1.4)
SIMPONI / SIMPONI ARIA
US			1,082						1,124						(3.8)			(3.8)			—
Intl			1,108						1,073						3.3			13.2			(9.9)
WW			2,190						2,197						(0.3)			4.5			(4.8)
STELARA
US			6,720						6,966						(3.5)			(3.5)			—
Intl			3,641						3,892						(6.4)			(3.3)			(3.1)
WW			10,361						10,858						(4.6)			(3.4)			(1.2)
TREMFYA
US			2,443						2,147						13.7			13.7			—
Intl			1,227						999						22.8			27.6			(4.8)
WW			3,670						3,147						16.6			18.1			(1.5)
OTHER IMMUNOLOGY
US			3						11						(74.1)			(74.1)			—
Intl			0						0						—			—			—
WW			3						11						(74.1)			(74.1)			—
INFECTIOUS DISEASES
US			1,354						1,500						(9.8)			(9.8)			—
Intl			2,042						2,918						(30.0)			(29.3)			(0.7)
WW			3,396						4,418						(23.1)			(22.7)			(0.4)
COVID-19 VACCINE
US			0						0						—			—			—
Intl			198						1,117						(82.4)			(82.4)			0.0
WW			198						1,117						(82.4)			(82.4)			0.0
EDURANT / rilpivirine
US			31						35						(10.0)			(10.0)			—
Intl			1,241						1,115						11.2			11.2			0.0
WW			1,272						1,150						10.6			10.6			0.0
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US			1,311						1,446						(9.4)			(9.4)			—
Intl			401						408						(1.7)			1.1			(2.8)
WW			1,712						1,854						(7.7)			(7.1)			(0.6)
OTHER INFECTIOUS DISEASES
US			11						19						(41.0)			(41.0)			—
Intl			203						278						(26.7)			(23.9)			(2.8)
WW			214						297						(27.6)			(25.0)			(2.6)

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			TWELVE MONTHS
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
NEUROSCIENCE
US			$4,398						4,065						8.2		%	8.2		%	—		%
Intl			2,718						3,076						(11.6)			(7.8)			(3.8)
WW			7,115						7,140						(0.4)			1.3			(1.7)
CONCERTA / methylphenidate
US			134						230						(41.7)			(41.7)			—
Intl			507						554						(8.4)			(4.1)			(4.3)
WW			641						783						(18.1)			(15.1)			(3.0)
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
US			3,125						2,897						7.9			7.9			—
Intl			1,097						1,218						(9.9)			(7.1)			(2.8)
WW			4,222						4,115						2.6			3.4			(0.8)
SPRAVATO
US			929						589						57.8			57.8			—
Intl			148						100						48.2			51.2			(3.0)
WW			1,077						689						56.4			56.8			(0.4)
OTHER NEUROSCIENCE
US			210						349						(39.8)			(39.8)			—
Intl			965						1,204						(19.8)			(15.1)			(4.7)
WW			1,175						1,553						(24.3)			(20.7)			(3.6)
ONCOLOGY
US			10,854						8,462						28.3			28.3			—
Intl			9,926						9,199						7.9			12.1			(4.2)
WW			20,781						17,661						17.7			19.8			(2.1)
CARVYKTI
US			869						469						85.2			85.2			—
Intl			94						30						*			*			*
WW			963						500						92.7			92.7			0.0
DARZALEX
US			6,588						5,277						24.8			24.8			—
Intl			5,082						4,467						13.8			19.1			(5.3)
WW			11,670						9,744						19.8			22.2			(2.4)
ERLEADA
US			1,282						1,065						20.3			20.3			—
Intl			1,717						1,322						29.8			32.9			(3.1)
WW			2,999						2,387						25.6			27.3			(1.7)
IMBRUVICA
US			1,020						1,051						(3.0)			(3.0)			—
Intl			2,018						2,214						(8.8)			(6.3)			(2.5)
WW			3,038						3,264						(6.9)			(5.2)			(1.7)
TECVAYLI
US			418						334						25.3			25.3			—
Intl			131						61						*			*			*
WW			549						395						38.8			39.8			(1.0)
ZYTIGA / abiraterone acetate
US			34						50						(32.2)			(32.2)			—
Intl			597						837						(28.6)			(24.6)			(4.0)
WW			631						887						(28.8)			(25.0)			(3.8)
OTHER ONCOLOGY
US			643						215						*			*			—
Intl			288						269						7.1			10.4			(3.3)
WW			931						484						92.5			94.3			(1.8)

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			TWELVE MONTHS
															% Change
			2024						2023						Reported			Operational(1)			Currency
INNOVATIVE MEDICINE SEGMENT(2)(Continued)
PULMONARY HYPERTENSION
US			$	3,143					2,697						16.5		%	16.5		%	—		%
Intl			1,140						1,117						2.0			8.2			(6.2)
WW			4,282						3,815						12.3			14.1			(1.8)
OPSUMIT
US			1,520						1,292						17.7			17.7			—
Intl			664						681						(2.4)			1.1			(3.5)
WW			2,184						1,973						10.7			11.9			(1.2)
UPTRAVI
US			1,511						1,326						13.9			13.9			—
Intl			307						255						20.1			27.3			(7.2)
WW			1,817						1,582						14.9			16.1			(1.2)
OTHER PULMONARY HYPERTENSION
US			112						79						41.8			41.8			—
Intl			169						182						(6.9)			8.2			(15.1)
WW			281						260						7.9			18.3			(10.4)
CARDIOVASCULAR / METABOLISM / OTHER
US			2,866						2,906						(1.4)			(1.4)			—
Intl			696						765						(9.1)			(7.1)			(2.0)
WW			3,562						3,671						(3.0)			(2.6)			(0.4)
XARELTO
US			2,373						2,365						0.3			0.3			—
Intl			—						—						—			—			—
WW			2,373						2,365						0.3			0.3			—
OTHER
US			494						541						(8.8)			(8.8)			—
Intl			696						765						(9.1)			(7.1)			(2.0)
WW			1,189						1,306						(8.9)			(7.8)			(1.1)
TOTAL INNOVATIVE MEDICINE
US			33,970						31,169						9.0			9.0			—
Intl			22,994						23,590						(2.5)			1.3			(3.8)
WW			$	56,964					54,759						4.0		%	5.7		%	(1.7)		%

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			TWELVE MONTHS
															% Change
			2024						2023						Reported			Operational(1)			Currency
MEDTECH SEGMENT(2)
CARDIOVASCULAR(4)
US			$	4,513					3,633						24.2		%	24.2		%	—		%
Intl			3,194						2,717						17.6			20.9			(3.3)
WW			7,707						6,350						21.4			22.8			(1.4)
ELECTROPHYSIOLOGY
US			2,738						2,458						11.4			11.4			—
Intl			2,529						2,230						13.4			17.0			(3.6)
WW			5,267						4,688						12.3			14.0			(1.7)
ABIOMED
US			1,213						1,066						13.7			13.7			—
Intl			284						240						18.2			20.3			(2.1)
WW			1,496						1,306						14.5			14.9			(0.4)
SHOCKWAVE(5)
US			442						—						*			*			—
Intl			122						—						*			*			—
WW			564						—						*			*			—
OTHER CARDIOVASCULAR(4)
US			120						109						10.7			10.7			—
Intl			260						247						5.3			7.3			(2.0)
WW			380						356						6.9			8.4			(1.5)
ORTHOPAEDICS
US			5,689						5,525						3.0			3.0			—
Intl			3,470						3,417						1.5			3.0			(1.5)
WW			9,158						8,942						2.4			3.0			(0.6)
HIPS
US			1,057						996						6.2			6.2			—
Intl			581						564						3.0			4.6			(1.6)
WW			1,638						1,560						5.0			5.6			(0.6)
KNEES
US			922						896						2.9			2.9			—
Intl			623						559						11.3			12.4			(1.1)
WW			1,545						1,456						6.1			6.5			(0.4)
TRAUMA
US			2,013						1,949						3.3			3.3			—
Intl			1,036						1,030						0.6			2.1			(1.5)
WW			3,049						2,979						2.3			2.9			(0.6)
SPINE, SPORTS & OTHER
US			1,696						1,684						0.7			0.7			—
Intl			1,230						1,263						(2.6)			(1.2)			(1.4)
WW			2,926						2,947						(0.7)			(0.1)			(0.6)

See footnotes at end of schedule

---

Johnson & Johnson

Segment sales

(Dollars in Millions)

			TWELVE MONTHS
															% Change
			2024						2023						Reported			Operational(1)			Currency
MEDTECH SEGMENT(2)(Continued)
SURGERY
US			$4,003						4,031						(0.7)		%	(0.7)		%	—		%
Intl			5,842						6,006						(2.7)			0.6			(3.3)
WW			9,845						10,037						(1.9)			0.1			(2.0)
ADVANCED
US			1,838						1,833						0.2			0.2			—
Intl			2,650						2,837						(6.6)			(3.5)			(3.1)
WW			4,488						4,671						(3.9)			(2.0)			(1.9)
GENERAL
US			2,165						2,198						(1.5)			(1.5)			—
Intl			3,192						3,168						0.8			4.3			(3.5)
WW			5,358						5,366						(0.2)			2.0			(2.2)
VISION
US			2,128						2,086						2.0			2.0			—
Intl			3,018						2,986						1.1			3.7			(2.6)
WW			5,146						5,072						1.5			3.0			(1.5)
CONTACT LENSES / OTHER
US			1,684						1,626						3.6			3.6			—
Intl			2,049						2,076						(1.3)			1.8			(3.1)
WW			3,733						3,702						0.8			2.6			(1.8)
SURGICAL
US			444						460						(3.4)			(3.4)			—
Intl			969						910						6.5			8.2			(1.7)
WW			1,413						1,370						3.2			4.3			(1.1)
TOTAL MEDTECH
US			16,332						15,275						6.9			6.9			—
Intl			15,525						15,125						2.6			5.4			(2.8)
WW			$31,857						30,400						4.8		%	6.2		%	(1.4)		%

Note: Column and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

*    Percentage greater than 100% or not meaningful

(1)Operational growth excludes the effect of translational currency

(2)Unaudited

(3)Reported as U.S. sales

(4)Previously referred to as Interventional Solutions

(5)Acquired on May 31, 2024

---

Supplemental sales information (unaudited)

(Dollars in Millions)

						FOURTH QUARTER
																		% Change
						2024						2023						Total			Operations			Currency
Innovative Medicine
U.S.						$	8,977					8,079						11.1		%	11.1			—
International						5,355						5,643						(5.1)			(1.0)			(4.1)
Worldwide						14,332						13,722						4.4			6.1			(1.7)
COVID-19 Vaccine
U.S.						—						—						—			—			—
International						—						44						*			*			*
Worldwide						—						44						*			*			*
Innovative Medicine excluding COVID-19 Vaccine
U.S.						8,977						8,079						11.1			11.1			—
International						5,355						5,599						(4.4)			(0.3)			(4.1)
Worldwide						14,332						13,678						4.8			6.5			(1.7)
Worldwide
U.S.						13,204						12,009						10.0			10.0			—
International						9,316						9,386						(0.7)			2.5			(3.2)
Worldwide						22,520						21,395						5.3			6.7			(1.4)
COVID-19 Vaccine
U.S.						—						—						—			—			—
International						—						44						*			*			*
Worldwide						—						44						*			*			*
Worldwide
U.S.						13,204						12,009						10.0			10.0			—
International						9,316						9,342						(0.3)			2.9			(3.2)
Worldwide excluding COVID-19 Vaccine						$	22,520					21,351						5.5			6.9			(1.4)
Europe						$	4,921					4,962						(0.8)			(0.2)			(0.6)
Europe COVID-19 Vaccine Sales						—						44						*			*			*
Europe excluding COVID-19 Vaccine						$	4,921					4,918						0.1			0.7			(0.6)

Note: Columns and rows within tables may not add due to rounding

* Percentage greater than 100% or not meaningful

---

Supplemental sales information (unaudited)

(Dollars in Millions)

						TWELVE MONTHS
																		% Change
						2024						2023						Total			Operations			Currency
Innovative Medicine
U.S.						$	33,970					31,169						9.0		%	9.0			—
International						22,994						23,590						(2.5)			1.3			(3.8)
Worldwide						56,964						54,759						4.0			5.7			(1.7)
COVID-19 Vaccine
U.S.						—						—						—			—			—
International						198						1,117						(82.4)			(82.4)			0.0
Worldwide						198						1,117						(82.4)			(82.4)			0.0
Innovative Medicine excluding COVID-19 Vaccine
U.S.						33,970						31,169						9.0			9.0			—
International						22,796						22,473						1.4			5.5			(4.1)
Worldwide						56,766						53,642						5.8			7.5			(1.7)
Worldwide
U.S.						50,302						46,444						8.3			8.3			—
International						38,519						38,715						(0.5)			2.9			(3.4)
Worldwide						88,821						85,159						4.3			5.9			(1.6)
COVID-19 Vaccine
U.S.						—						—						—			—			—
International						198						1,117						(82.4)			(82.4)			0.0
Worldwide						198						1,117						(82.4)			(82.4)			0.0
Worldwide
U.S.						50,302						46,444						8.3			8.3			—
International						38,321						37,598						1.9			5.5			(3.6)
Worldwide excluding COVID-19 Vaccine						$	88,623					84,042						5.5		%	7.0			(1.5)
Europe						$	20,212					20,410						(1.0)		%	(0.6)			(0.4)
Europe COVID-19 Vaccine Sales						198						1,117						(82.4)			(82.4)			0.0
Europe excluding COVID-19 Vaccine						$	20,014					19,293						3.7		%	4.1			(0.4)

Note: Columns and rows within tables may not add due to rounding